paclitaxelhttp://www.unboundmedicine.com/medline/ebm/research/paclitaxelUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.No Association of Chromosome 9p21.3 Variation With Clinical and Angiographic Outcomes After Placement of Drug-Eluting Stents.http://www.unboundmedicine.com/medline/ebm/record/19926059/full_citation/No_Association_of_Chromosome_9p21_3_Variation_With_Clinical_and_Angiographic_Outcomes_After_Placement_of_Drug_Eluting_Stents_Hoppmann P, Erl A, Türk S, et al. 
No Association of Chromosome 9p21.3 Variation With Clinical and Angiographic Outcomes After Placement of Drug-Eluting Stents. [JOURNAL ARTICLE]
JACC Cardiovasc Interv 2009 Nov; 2(11):1149-1155.
Abstract | Full Citation | Find Related Articles Lesion Complexity Determines Arterial Drug Distribution After Local Drug Delivery.http://www.unboundmedicine.com/medline/ebm/record/19925836/full_citation/Lesion_Complexity_Determines_Arterial_Drug_Distribution_After_Local_Drug_Delivery_Tzafriri AR, Vukmirovic N, Kolachalama VB, et al. 
Lesion Complexity Determines Arterial Drug Distribution After Local Drug Delivery. [JOURNAL ARTICLE]
J Control Release 2009 Nov 16.
Abstract | Full Citation | Find Related Articles Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes.http://www.unboundmedicine.com/medline/ebm/record/19925835/full_citation/Polyester_based_micelles_and_nanoparticles_for_the_parenteral_delivery_of_taxanes_Gaucher G, Marchessault RH, Leroux JC 
Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes. [JOURNAL ARTICLE]
J Control Release 2009 Nov 16.
Abstract | Full Citation | Find Related Articles Intravenous-to-Oral Switch in Anticancer Chemotherapy: A Focus on Docetaxel and Paclitaxel.http://www.unboundmedicine.com/medline/ebm/record/19924122/full_citation/Intravenous_to_Oral_Switch_in_Anticancer_Chemotherapy:_A_Focus_on_Docetaxel_and_Paclitaxel_Koolen SL, Beijnen JH, Schellens JH 
Intravenous-to-Oral Switch in Anticancer Chemotherapy: A Focus on Docetaxel and Paclitaxel. [JOURNAL ARTICLE]
Clin Pharmacol Ther 2009 Nov 18.
Full Citation | Publisher Full Text | Find Related Articles [Pharmacological bases of intraperitoneal chemotherapy.]http://www.unboundmedicine.com/medline/ebm/record/19923051/full_citation/[Pharmacological_bases_of_intraperitoneal_chemotherapy_]Gladieff L, Chatelut E, Dalenc F, et al. 
[Pharmacological bases of intraperitoneal chemotherapy.] [JOURNAL ARTICLE]
Bull Cancer 2009 Nov 18.
Abstract | Full CitationAlternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.http://www.unboundmedicine.com/medline/ebm/record/19922987/full_citation/Alternative_intraperitoneal_chemotherapy_regimens_for_optimally_debulked_ovarian_cancer_Gray HJ, Shah CA, Swensen RE, et al. 
Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer. [JOURNAL ARTICLE]
Gynecol Oncol 2009 Nov 16.
Abstract | Full CitationOxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue.http://www.unboundmedicine.com/medline/ebm/record/19922644/full_citation/Oxaliplatin_induced_loss_of_phosphorylated_heavy_neurofilament_subunit_neuronal_immunoreactivity_in_rat_DRG_tissue_Jamieson SM, Subramaniam J, Liu JJ, et al. 
Oxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue. [JOURNAL ARTICLE]
Mol Pain 2009 Nov 18; 5(1):66.
Abstract | Full Citation | Find Related Articles Current status of chemotherapy in risk-adapted management for metastatic testicular germ cell cancer.http://www.unboundmedicine.com/medline/ebm/record/19922501/full_citation/Current_status_of_chemotherapy_in_risk_adapted_management_for_metastatic_testicular_germ_cell_cancer_Kawai K, Akaza H 
Current status of chemotherapy in risk-adapted management for metastatic testicular germ cell cancer. [JOURNAL ARTICLE]
Cancer Sci 2009 Sep 26.
Abstract | Full Citation | Find Related Articles Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study.http://www.unboundmedicine.com/medline/ebm/record/19920864/full_citation/Non_Cross_Resistant_Sequential_Single_Agent_Chemotherapy_in_First_Line_Advanced_Non_Small_Cell_Lung_Cancer_Patients:_Results_of_a_Phase_II_Study_Surmont V, Aerts JG, Tan KY, et al. 
Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study. [JOURNAL ARTICLE]
J Oncol 2009.:457418.
Abstract | Full Citation | Find Related Articles [A Case of Advanced Gastric Cancer That a Medical Therapy Effect Was Provided Grade 3 by a Histopathological Diagnosis after Long-Term Chemotherapy.]http://www.unboundmedicine.com/medline/ebm/record/19920392/full_citation/[A_Case_of_Advanced_Gastric_Cancer_That_a_Medical_Therapy_Effect_Was_Provided_Grade_3_by_a_Histopathological_Diagnosis_after_Long_Term_Chemotherapy_]Oya H, Honda I, Hirabayashi S, et al. 
[A Case of Advanced Gastric Cancer That a Medical Therapy Effect Was Provided Grade 3 by a Histopathological Diagnosis after Long-Term Chemotherapy.] [JOURNAL ARTICLE]
Gan To Kagaku Ryoho 2009 Nov; 36(11):1881-1884.
Abstract | Full Citation | Find Related Articles